SOUTH PLAINFIELD, NJ -- (Marketwire) -- 12/03/12 -- GENEWIZ, Inc., leading global genomic service provider, announced today expansion of their Next Generation Sequencing service portfolio to include Cancer Panels. Available through Illumina and Life Technologies platforms, Cancer Panels enable GENEWIZ to screen for genetic mutations proven to play a role in cancer.
Advanced next generation sequencing technologies enable cancer panels to target over fifty cancer genes with deep sequencing, providing a high depth of coverage sensitive enough to detect rare mutations from a very small amount of DNA.
"NGS-based cancer panels allow for rapid analysis of multiple genes at a considerably lower price compared to traditional sequencing techniques," stated Dr. Yankai Jia, Director of GENEWIZ Next Generation Sequencing. "The large amount of data generated is highly technical, so it's important for researchers to have a trusted partner throughout the process who can provide the customized support and scientific expertise required."
In addition to offering the Ion AmpliSeq and TruSeq® Cancer Panels, GENEWIZ is actively developing custom cancer panels in effort to further advance cancer research, biomarker discovery, clinical diagnostics, and personalized medicine.
For more information about GENEWIZ Next Generation Sequencing Cancer Panels, please click here.
About GENEWIZ, Inc.
GENEWIZ, Inc. is a global contract research organization (CRO) specializing in genomic services, including DNA sequencing, gene synthesis, molecular biology, genomic, bioinformatics, and GxP/CLIA regulatory-compliant services. GENEWIZ leads the industry in outsourcing partnerships with pharmaceutical, biotechnology, clinical, academic, and government institutions.
Headquartered in South Plainfield, NJ, GENEWIZ, Inc. is a privately-held global enterprise with locations in Boston, MA; San Diego, CA; Washington, DC Metro; Research Triangle Park, NC; and Seattle, WA. International locations include Beijing, China; Suzhou, China; and London, United Kingdom.